Cartalax
Preclinical ResearchCartalax (Ala-Glu-Asp)
A Khavinson bioregulator tripeptide studied for cartilage and connective tissue regulation.
Dose
500 mcg
Route
Subcutaneous injection
Cycle
10-20 days
Storage
2-8°C (refrigerator) away from light
What is Cartalax?
Cartalax is a synthetic tripeptide (Lys-Glu-Asp or KED) belonging to the class of Khavinson bioregulator peptides. These peptides are characterized by their short amino acid sequences and are hypothesized to exert tissue-specific regulatory effects. Cartalax is specifically studied for its potential role in regulating cartilage tissue function and metabolism. Research, primarily in preclinical models, suggests it may influence cell proliferation, differentiation, and matrix synthesis in chondrocytes, potentially supporting cartilage integrity and repair processes. It is generally supplied as a lyophilized powder for reconstitution.
Key Benefits
- Cartilage tissue research
🐾 Griffin Says...
Molecular Information
Molecular weight
377.37 g/mol
Type
Khavinson Bioregulator Peptide
Amino acid sequence
Lys-Glu-Asp
Also known as KED peptide, representing the amino acid sequence Lysine-Glutamic acid-Aspartic acid.
Research Indications
Cartilage Regulation
Animal and in-vitro studies suggest Cartalax may influence chondrocyte proliferation and differentiation, as well as extracellular matrix synthesis, indicating a potential role in cartilage tissue regulation. Evidence is preclinical only.
Connective Tissue Support
Some preclinical research explores its potential to support overall connective tissue integrity due to its proposed bioregulatory action. Evidence is preclinical only.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Basic Cartilage Regulation Research | 500 mcg | Once daily | Subcutaneous |
| Extended Cartilage Support Research | 500 mcg | Once daily | Subcutaneous |
| In-vitro Chondrocyte Studies | Varied (e.g., 10-100 µg/mL) | As per experimental design | Cell culture medium |
| Animal Model for Joint Research | 0.1-0.5 mg/kg (dependent on animal model) | Once daily or every other day | Subcutaneous or intraperitoneal |
Research protocols typically involve daily subcutaneous injections for a defined period, followed by an extended break.
Peptide Interactions
- Monitor Combination
NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
No direct interaction data for Cartalax, but NSAIDs are commonly used in models of joint inflammation. Researchers should monitor for additive or confounding effects on study outcomes if used concurrently in animal models.
- Use Caution
Corticosteroids
Corticosteroids can affect cartilage metabolism. Concurrent use in research models may obscure or alter the specific effects of Cartalax; careful experimental design and interpretation are required.
- Monitor Combination
Growth Factors (e.g., IGF-1)
Growth factors also influence cell proliferation and differentiation. Combination studies could explore synergistic or antagonistic effects on cartilage repair, requiring careful observation and analysis.
- Monitor Combination
Other Bioregulator Peptides
While bioregulators are designed for tissue specificity, the effects of combining multiple peptides simultaneously on cartilage or other systems are not well-studied and require careful investigation.
How to Reconstitute
- 1Gather supplies: Cartalax vial, bacteriostatic water (BW), sterile syringe (e.g., 1mL), alcohol wipes.
- 2Clean the rubber stopper of the Cartalax vial and the BW vial with separate alcohol wipes.
- 3Draw 1 mL (or desired volume for concentration) of BW into the syringe.
- 4Slowly inject the BW into the Cartalax vial, aiming the needle at the side of the vial to allow water to run down gently.
- 5Remove the syringe and gently swirl the vial in a circular motion until the lyophilized powder is completely dissolved. Do not shake vigorously.
- 6Visually inspect the solution for any undissolved particles or discoloration. The solution should be clear.
Use bacteriostatic water for reconstitution to maintain sterility and prolong stability. Avoid vigorous shaking; gently swirl the vial until the powder is fully dissolved.
What to Expect
- Subcutaneous administration may cause mild, temporary discomfort, redness, or bruising at the injection site.
- Effects on cartilage and connective tissue are typically subtle and require consistent administration over the entire research cycle.
- Observations in animal models suggest potential improvements in markers of cartilage health or reduced degradation, but these are not immediate.
- Systemic effects are not commonly reported in preclinical research with Cartalax at standard research doses.
- Consistency in administration timing and dose is generally considered important for optimal research outcomes.
Side Effects & Safety
- This compound is for research purposes only and not for human consumption or therapeutic use. Handle with appropriate laboratory safety precautions.
- Ensure proper sterile technique during reconstitution and administration to minimize the risk of infection.
- Dispose of all needles and syringes in an approved sharps container.
- Store the lyophilized and reconstituted peptide according to specified temperatures to maintain stability and potency for research.
- Monitor for any signs of allergic reaction or unexpected adverse effects during research. Discontinue use if observed.
- Keep out of reach of children and pets.
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open CalculatorPeptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.